# Robert I. Haddad

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-i-haddad/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,317 |
| Field | Head and Neck Cancer Studies |
| h-index | 92 |
| i10-index | 294 |
| OpenAlex ID | https://openalex.org/A5080875822 |
| ORCID iD | https://orcid.org/0000-0003-1413-0079 |
| Works | 790 |

## Researcher papers

- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)
- [Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression](https://scholariq.org/papers/nivolumab-vs-investigator-s-choice-in-recurrent-or-metastatic-squamous-cell/)
- [Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors](https://scholariq.org/papers/genomic-correlates-of-response-to-immune-checkpoint-blockade-in-microsatellite/)
- [Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study](https://scholariq.org/papers/pembrolizumab-for-platinum-and-cetuximab-refractory-head-and-neck-cancer-results/)
- [Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial](https://scholariq.org/papers/neoadjuvant-and-adjuvant-pembrolizumab-in-resectable-locally-advanced-human/)

## Researcher topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Diagnosis and Treatment](https://scholariq.org/topics/cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.